Success Metrics

Clinical Success Rate
100.0%

Based on 3 completed trials

Completion Rate
100%(3/3)
Active Trials
1(25%)
Results Posted
100%(3 trials)

Phase Distribution

Ph not_applicable
2
50%

Phase Distribution

0

Early Stage

0

Mid Stage

0

Late Stage

Phase Distribution2 total trials
N/ANon-phased studies
2(100.0%)

Highest Phase Reached

Unknown

Trial Status & Enrollment

Completion Rate

100.0%

3 of 3 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

1

trials recruiting

Total Trials

4

all time

Status Distribution
Active(1)
Completed(3)

Detailed Status

Completed3
Active, not recruiting1

Development Timeline

Analytics

Development Status

Total Trials
4
Active
1
Success Rate
100.0%
Most Advanced
N/A

Trials by Phase

N/A2 (100.0%)

Trials by Status

active_not_recruiting125%
completed375%

Recent Activity

1 active trials
Showing 4 of 4
active_not_recruitingnot_applicable

POLARx Post Approval Study (POLARx PAS)

NCT06170606
completed

POLARx™ Cardiac Cryoablation System Post Market Clinical Study (POLAR SMART)

NCT05282823
completed

POLARx Cardiac Cryoablation System Study

NCT04250714
completednot_applicable

Boston Scientific's Cryoballoon in the Treatment of Symptomatic Drug Refractory Paroxysmal Atrial Fibrillation

NCT04133168

Clinical Trials (4)

Showing 4 of 4 trials
NCT06170606Not Applicable

POLARx Post Approval Study (POLARx PAS)

Active Not Recruiting
NCT05282823

POLARx™ Cardiac Cryoablation System Post Market Clinical Study (POLAR SMART)

Completed
NCT04250714

POLARx Cardiac Cryoablation System Study

Completed
NCT04133168Not Applicable

Boston Scientific's Cryoballoon in the Treatment of Symptomatic Drug Refractory Paroxysmal Atrial Fibrillation

Completed

All 4 trials loaded

Drug Details

Intervention Type
DEVICE
Total Trials
4